Report of Foreign Issuer (6-k)
March 29 2019 - 6:24AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of
1934
For the month of March, 2019
Commission File Number 001-38522
Realm Therapeutics plc
(Translation of registrant’s name
into English)
267 Great Valley Parkway
Malvern, PA 19355
(Address of principal executive office)
Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT
ON FORM 6-K
On March 29, 2019, Realm Therapeutics plc
(the “Company”) announced
the completion of the Assets Disposal representing
certain Assets, which comprise the Vashe® wound care royalty stream, an
FDA
510(k)-cleared
anti-itch hydrogel, which was formerly marketed as Aurstat™, HOCI related equipment, intellectual property (including know-how,
patents and copyrights), program records, and certain assigned contracts and intellectual property licenses (as detailed in the
Circular to Shareholders issued on February 15, 2019). Gross proceeds of the sale are $10 million.
Realm
continues to assess options available to maximize shareholder value through the strategic review. The Company remains in discussions
with interested parties regarding a potential strategic transaction and will update the market in early Q2 2019.
T
he
net proceeds of the Assets Disposal will augment the Company’s current cash resources, which may be deployed in event of
such a transaction.
Capitalized
terms used but not defined in this announcement shall have the meanings given to them in the circular sent to Realm shareholders
on February 15, 2019, which remains available on the Company's website at
www.realmtx.com
.
The Exhibit to this Report on Form 6-K
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any
filing of the Company under the Securities Act of 1933 or the Exchange Act.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Realm Therapeutics plc
|
|
|
|
|
March 29, 2019
|
|
|
|
By:
|
|
/s/ Marella Thorell
|
|
|
|
|
|
|
Marella Thorell
|
|
|
|
|
|
|
Chief Financial Officer and Chief Operating Officer
|
Realm Therapeutics (NASDAQ:RLM)
Historical Stock Chart
From May 2024 to Jun 2024
Realm Therapeutics (NASDAQ:RLM)
Historical Stock Chart
From Jun 2023 to Jun 2024